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Abstract Stroke is the third leading cause of death and the
leading cause of disability in Western countries. More than
60% of patients remain disabled, 50% of patients suffer from
some hemiparesis and 30% remain unable to walk without
assistance. The skeletal muscle is the main effector organ
accountable fordisabilityinstroke.Thisdisabilityis,however,
traditionally attributed to the brain injury itself and less
attention is paid to structural, metabolic and functional aspects
of muscle tissue. Hemiparetic stroke leads to various muscle
abnormalities. A combination of denervation, disuse, inflam-
mation, remodelling and spasticity account for a complex
pattern of muscle tissue phenotype change and atrophy. While
the molecular mechanisms of muscle degradation after stroke
are only incompletely understood, a stroke-related sarcopenia
may be concluded. Reinnervation, fiber-type shift, disuse
atrophyandlocalinflammatoryactivationareonlysomeofthe
key features to be addressed. Despite the importance for
optimum post stroke recovery, stroke-related sarcopenia is not
recognised in current guidelines for stroke therapy and
rehabilitation. A total of not more than 500 patients forms
the basis for all available evidence on clinical muscle changes
after stroke. A lack of robust evidence on muscle pathology
after stroke and on treatment strategies becomes apparent that
needs to be addressed in an interdisciplinary integrated
approach.
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1 Introduction
Sarcopenia is primarily a disease of the elderly. In view of the
constantly older growing population of our modern society, it
is therefore a very timely approach to address those muscle-
related problems in a newly designed and specific journal [1].
Accumulation of data on structural, metabolic and functional
characteristics of skeletal muscle will provide a solid
platform to cross-fertilize between clinical and basic science
specialties. Thus, the impact of skeletal muscle on disease
progression or recovery processes may become apparent.
Until now, this often goes unrecognised or underestimated as
minor side effect of the primary disease.
Stroke may serve as a prime example how skeletal
muscle may be of utmost importance for the outcome of
patients and yet limited attention is focussed on metabolic
and functional alterations in skeletal muscle after stroke. An
interdisciplinary approach on the peripheral metabolic
implications of stroke is warranted to complement brain-
and neuro-specific perspectives to achieve an integrated
perspective on patients with stroke.
2 Stroke—a growing problem
Stroke is one of the leading causes of death in industrialised
countries ranging just behind cardiac- and cancer-related
causes. Stroke incidence varies across Europe between 100
and 700 events per 100,000 inhabitants being highest in
Eastern European countries (Lithuania and Poland) and
lowest in south Europe (Italy and Spain) [2]. Stroke
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per year of which approximately one quarter are recurrent
strokes[3]. In 2008, a stroke prevalence of 7,000,000 patients
has been estimated for the US with an average of one patient
dying from stroke every 4 min [4]. Stroke is also the single
greatest cause of disability in the adult population in modern
society [5]. Even with optimal acute therapy, about two thirds
of patients remain in a state of incomplete recovery after
stroke [6], 15–30% are permanently disabled and 20%
require institutional care at 3 months after onset [3].
Rehabilitation efforts are pivotal to optimize functional
recovery after stroke and the benefit of rehabilitation is
beyond doubt. Yet, assignment of patient to rehabilitation is
largely dependent of the structured health care system and
may vary between countries. A US national survey in 2005
observed that only 31% of stroke survivors received
outpatient rehabilitation [3]. This number was considerably
lower than expected if clinical practice guideline recommen-
dations for all stroke patients had been followed.
3 Stroke and skeletal muscle changes
Long-term disability is the most frequent complication after
stroke with 50% of patients suffering from some hemiparesis
and 30% being unable to walk without assistance [7].
Hemiparetic stroke leads to muscle abnormalities with a
combination of denervation, disuse, remodelling and spas-
ticity that may account for a complex pattern of phenotype
shift and atrophy. Structural adaptive changes in muscle
tissue were observed to start as early as 4 h after cerebral
infarction. They may be related to disrupted synaptic
transmission of the muscle innervating motor neurons and
lead to the reduction of motor unit numbers [8]. Interestingly,
muscle weakness develops as well in the unaffected limb
within 1 week after paretic stroke [9].
3.1 Stroke and fiber-type shift
Human skeletal muscle fibres have great adaptive potential;
yet, molecular mechanisms of the atrophy and phenotype
shift after stroke are not known in great detail. In normal
ageing, muscle tissue changes are characterised by a shift in
fiber-type distribution with decrease in fast-twitch muscle
(MHC type IIa and IIb) fibers and increase in mitochondria-
rich slow-twitch (MHC type I) muscle fibers that results
also in reduction of muscle strength. Thus, between 30 and
60 years of age, muscle strength decreased by 18% and
between the seventh and ninth decade another 20% were
lost [10]. This fiber-type shift results from motor unit
denervation and subsequent reinnervation from adjacent
intact muscle fibres. In contrast to the age-dependent shift
from fast-twitch to slow-twitch fibres, an inverse shift
towards increased fast-twitch MHC type II isoforms with
more reliance on anaerobic metabolism has been observed
in stroke [11]. This fiber-type shift was a strong predictor
of impaired functional capacity such as gait deficit
severity after stroke. To what degree this stroke-induced
denervation and reinnervation contributes to stroke spe-
cific phenotype shift of skeletal muscle tissue needs
further evaluation.
3.2 Stroke and disuse atrophy
Inactivity and immobilisation after stroke are also important
factors as muscle unloading produces a multitude of (mal-)
adaptive responses of muscle tissue. Hence, it has been
reported that patients with acute stroke were physically active
for less than 40 min a day during hospitalisation [12].
Inactivity results, among others, in insulin resistance, which
not only affects glucose-dependent energy metabolism but
also leads to decreased anabolic stimulation from insulin.
Only 10 days of bed rest in healthy older adults has been
shown to induce a 30% decrease in muscle protein synthesis
and a 6% reduced leg lean mass that results in 16% reduced
muscle strength [13]. Notably, nutritional status is often
reduced already at stroke occurrence [14], undernutrition
continues while hospitalised [15] and feeding difficulties
often persist thereafter. Hence, in stroke patients, an even
accelerated tissue wasting due to combined insufficient
nutritional supply and anabolic failure may be more realistic.
The long-term muscle changes such as loss in muscle
mass, reduction of cross-sectional area and increased
intramuscular fat deposition occur between 3 weeks and
6 months in both paretic and non-paretic limbs [16, 17].
One would expect that the loss of muscle mass after stroke
is accompanied by weight reduction although replacement
of lean tissue by increased fat mass has been observed [18].
In fact, according to a recent population-based study from
the Lund stroke registry with a cohort of 305 patients,
weight loss of over 3 kg within a short-term (4 months) and
a medium-term (1 year) period after stroke was found in
about one quarter of patients [19]. However, a recent
systematic review reported about the presence of malnutri-
tion ranging from 8 to 49% among stroke patients [20] that
would contribute to weight loss as well. It may need further
pathophysiologic studies to decide if these processes
qualify as development of cachexia according to the current
definition [21] or if these processes represent sarcopenia
[22].
3.3 Stroke-related sarcopenia
While sarcopenia may occur in the course of normal ageing,
specific disease-related sarcopenia (or myopenia) should be
considered in conditions where accelerated muscle wasting
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described sarcopenia in sepsis and cancer [23, 24]. It needs
to be determined whether disease-specific mechanisms are
responsible for distinct types of muscle tissue degradation
or whether a common pathophysiologic pathway accounts
for a more or less uniform muscle catabolic process in
those diseases [25]. Given the stroke-induced alterations in
muscle tissue characteristics, a specific stroke-related
sarcopenia might be concluded that resembles age-
dependent sarcopenia in some characteristics but contrast-
ing it in others.
Interestingly, although the skeletal muscle is the main
effector organ accountable for disability in stroke, this
disability is traditionally attributed to the brain injury itself.
Considerable less attention is paid to the secondary abnor-
malities of muscle atrophy, metabolic and contractile capacity
and local inflammatory milieu. A recent systematic review
was undertaken to accumulate all clinical study data on
changes in skeletal muscle mass, volume or cross-sectional
area in stroke patients [26]. Out of 17,042 related publication
hits from the initial database search, mere 14 studies were
identified with a total of 490 patient participants that were
studied either cross-sectionally or in longitudinal studies.
Emerging data suggest that skeletal muscle (mal-) adaptive
processes importantly contribute to disability after stroke and
that exercise interventions may clearly be useful strategies to
prevent muscle wasting and restore physical capacity and
mobility after stroke. More work is warranted to define the
importance of this peripheral catabolic aspect of stroke
physiology.
4 Muscle wasting in stroke—not appreciated
in the guidelines
Todate,theissueofstroke-relatedsarcopeniaisnotrecognized
with all its clinical implications in relevant European or North
American stroke guidelines [27, 28]. Despite clinical studies
observed muscle loss after stroke contributing to disability
and adverse outcome after stroke, the guideline recommen-
dations do not consider prevention of muscle wasting after
stroke as relevant target. Also rehabilitation-orientated guide-
lines do not consider prevention of muscle wasting or
restored anabolic capacity as relevant interventional targets
[29, 30]. This currently under-represented aspect will need to
be appreciated more thoroughly within an interdisciplinary
concept of stroke rehabilitation. Certainly, physical activity in
the form of exercise rehabilitation belongs to the standard
therapy after stroke [31], prevention or restoring of muscle
metabolic abnormalities will substantially contribute to this.
Thus, a clinical study in older acute stroke patients revealed
that nutritional supplementation within the first week in
hospital has a beneficial effect for maintaining an adequate
body mass and body composition [32]. While the former
study used global high caloric and protein supplementation,
selective supplementations such as of essential amino acids
may have advantages in preserving muscle metabolic
integrity and function [33]. We are only at the beginning to
define optimum nutritional strategies in this context with
regard to amount, timing, content, etc. Muscle metabolic
abnormalities and sarcopenia are challenging areas for future
work towards an integrated and interdisciplinary approach on
stroke patients.
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